Bli medlem
Bli medlem

Du är här

2016-04-12

Biotie Therapies Oyj: Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016
at 4.15 p.m.

Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the
"Company") has on April 11, 2016 received a notification in accordance with
Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant
Ventures V, LLC on behalf of itself and Versant Venture Capital V, L.P.

According to the notification, the total number of Biotie shares owned
directly or through financial instruments by Versant Ventures V, LLC and its
funds has fallen below the threshold of 5 per cent on 11 April, 2016.
Biotie's registered total number of shares and voting rights amounting to
1,089,608,083 has been used in the calculation of percentages for the
announcement.

Total positions of Versant Ventures V, LLC and its funds subject to the
notification:

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| % of shares and voting rights (total of A) % of shares and voting rights through financial instruments Total of both in % (A+B) |
| (total of B) |
| Resulting situation on the date on which threshold was crossed or Below 5 % Below 5 % Below 5 % |
|reached |
| Position of previous notification (if applicable) 5.39 3.41 8.80 |
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Notified details of the resulting situation on the date on which the threshold
was crossed or reached:

A: Shares and voting rights

------------------------------------------------------------------------------------------------------------------------------------
| Class/type of shares Number of shares and voting rights % of shares and voting rights |
| |
|ISIN code (if possible) |
| Direct Indirect Direct Indirect |
| |
| (SMA 9:5) (SMA 9:6 and 9:7) (SMA 9:5) (SMA 9:6 and 9:7) |
| Shares - - - - |
| |
|(FI0009011571) |
| American Depositary Shares (ADS), each representing 80 Shares - - - - |
| |
|(FI0009011571) |
| |
| SUBTOTAL A Below 5 % |
------------------------------------------------------------------------------------------------------------------------------------
B: Financial instruments according to SMA 9:6a

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Type of financial instrument Expiration date Exercise/ Physical or cash settlement Number of shares and voting rights % of shares and voting rights |
| |
| Conversion period |
| Warrants entitling to subscribe for Shares Nov 1, 2020 Nov 1, 2015 - Nov 1, 2020 Physical settlement - - |
|(FI0009011571) |
| |
| SUBTOTAL B Below 5 % |
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Full chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

---------------------------------------------------------------------------------------------------------------------------------------------------------
| Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both |
| Versant Ventures V, LLC Below 5 % Below 5 % Below 5 % |
| Versant Venture Capital V, L.P. Below 5 % Below 5 % Below 5 % |
| Versant Affiliates Fund V, L.P. Below 5 % Below 5 % Below 5 % |
| Versant Ophthalmic Affiliates Fund I, L.P. Below 5 % Below 5 % Below 5 % |
| Versant Ventures V GP-GP (Canada), Inc. Below 5 % Below 5 % Below 5 % |
| Versant Ventures V (Canada), L.P. Below 5 % Below 5 % Below 5 % |
| Versant Venture Capital V (Canada) LP Below 5 % Below 5 % Below 5 % |
---------------------------------------------------------------------------------------------------------------------------------------------------------
According to the notification, Versant Ventures V, LLC is the sole general
partner of (i) Versant Venture Capital V, L.P. (ii) Versant Affiliates Fund
V, L.P. and (iii) Versant Ophthalmic Affiliates Fund I, L.P. and (iv) the
sole shareholder of Versant Ventures V GP-GP (Canada), Inc. Versant Ventures
V GP-GP (Canada), Inc. is the sole general partner of Versant Ventures V
(Canada), L.P., which is the sole general partner of Versant Venture Capital
V (Canada) LP. Neither Versant Ventures V, LLC nor any other entity under its
control holds shares or financial instruments in the Company exceeding a
notification threshold. Further, according to the notification, the
investments of the Versant Venture III funds (controlled by Versant Ventures
III, LLC) are under the Finnish Securities Markets Act not to be aggregated
with the investments of the funds controlled by Versant Ventures V, LLC for
the purposes of this notification.

In Turku, April 12, 2016

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:

Nasdaq Helsinki Ltd
Main Media
www.biotie.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

HUG#2002851

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.